Growth factors: To cleave or not to cleave

Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PCs): A New Potential Strategy in Cancer Therapy

Volumn , Issue , 2006, Pages 121-135

  Khatib, Abdel Majid ^a,b   Geraldine, Siegfried ^c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Growth factors; Proprotein convertases

Indexed keywords

EID: 61549092936     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-5132-8_7     Document Type: Chapter

References (64)

1. Siegfried G, Khatib AM, Benjannet S, Chretien M, Seidah NG (2003) The proteolytic processing of pro-platelet-derived growth factor-A at RRKR (86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 63:1458-1463.
2. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, Seidah NG, Khatib AM (2003) The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111:1723-1732.
3. Lee R, Kermani P, Teng KK., Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294:1945-1948.
4. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160:1921-1935.
5. Fukumoto S (2005) Post-translational modification of Fibroblast Growth Factor 23. Ther Apher Dial 9:319-322.
6. Seidah NG, Chretien M (1999) Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Res 848:45-62.
7. Seidah NG, Prat A (2002) Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 38:79-94.
8. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100:928-933.
9. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chretien M, Prat A, Seidah NG (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279:48865-48875.
10. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316.
11. Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A (2000) Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 13:632-637.
12. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729-3735.
13. Heldin CH, Rönnstrand L (1997) Growth factor receptors in cell transformation. In: Peters G, Vousden K (eds), Frontiers in Molecular Biology: Oncogenes and Tumor Suppressor Genes, Oxford, Oxford University Press, pp 55-85.
14. Hart CE, Bailey M, Curtis DA, Osborn S, Raines E, Ross R, Forstom JW (1990) Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry 29:166-172.
15. Robbins KC, Antoniades HN, Devare SG, Hunkapiller MW, Aaronson SA (1983) Structural and immunological similarities between simian sarcoma virus gene product(s) and human plateletderived growth factor. Nature 305:605-608.
16. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U (2000) PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2:302-309.
17. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U (2001) PDGF-D is a specific, protease-activated ligand for the PDGF beta- receptor. Nat Cell Biol 3:512-516.
18. Siegfried G, Basak A, Prichett-Pejic W, Scamuffa N, Ma L, Benjannet S, Veinot JP, Calvo F, Seidah N, Khatib AM (2005) Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. Oncogene 24:6925-6935.
19. Mercola M, Deininger PL, Shamah SM, Porter J, Wang CY, Stiles CD (1990) Dominant-negative mutants of a platelet-derived growth factor gene. Genes Dev 4:2333-2341.
20. LaRochelle WJ, May-Siroff M, Robbins KC, Aaronson SA (1991) A novel mechanism regulating growth factor association with the cell surface: identification of a PDGF retention domain. Genes Dev 5:1191-1199.
21. Rolny C, Spillmann D, Lindahl U, Claesson-Welsh L (2002) Heparin amplifies platelet-derived growth factor (PDGF)- BB-induced PDGF alpha -receptor but not PDGF beta -receptor tyrosine phosphorylation in heparan sulfate-deficient cells. Effects on signal transduction and biological responses. J Biol Chem 277:19315-19321.
22. Eming SA, Yarmush ML, Krueger GG, Morgan JR (1999) Regulation of the spatial organization of mesenchymal connective tissue: Effects of cell-associated versus released isoforms of plateletderived growth factor. Am J Pathol 154:281-289.
23. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298.
24. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K (1997) Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898-3911.
25. Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K (1998) Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 177:439-452.
26. Duguay SJ, Lai-Zhang J, Steiner DF (1995) Mutational analysis of the insulin-like growth factor I prohormone processing site. J Biol Chem 270:17566-17574.
27. Duguay SJ, Milewski WM, Young BD, Nakayama K, Steiner DF (1997) Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases. J Biol Chem 272:6663-6670.
28. Daughaday WH, Rotwein P (1989) Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68-91.
29. Lehmann M, Andre F, Bellan C, Remacle-Bonnet M, Garrouste F, Parat F, Lissitsky JC, Marvaldi J, Pommier G (1998) Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells. Endocrinology 139:3763-3771.
30. Duguay SJ, Jin Y, Stein J, Duguay AN, Gardner P, Steiner DF (1998) Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis. J Biol Chem 273:18443-18451.
31. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566.
32. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396.
33. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC (2001) IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: Association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 85:1695-1699.
34. Lukanova A, Toniolo P, Akhmedkhanov A (2001) A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 92:888-892.
35. Holthuizen PE, Cleutjens CB, Veenstra GJ, van der Lee FM, Koonen-Reemst AM, Sussenbach JS (1993) Differential expression of the human, mouse and rat IGF-II genes. Regul Pept 48:77-89.
36. DeChiara TM, Robertson EJ, Efstratiadis A (1991) Parental imprinting of the mouse insulin-like growth factor II gene. Cell 22:849-859.
37. Halloran BP, Nissenson RA (eds) (1992) Parathyroid Hormone-related Protein: Normal Physiology and Its Role in Cancer, CRC Press, Boca Raton, FL.
38. Kemper B, Habener JF, Mulligan R, Potts JT Jr, Rich A (1974) Pre-proparathyroid hormone: A direct translation product of parathyroid messenger RNA. Proc Natl Acad Sci USA 71:3731-3735.
39. Habener JF, Amherdt M, Ravazzola M, Orci L (1979) Parathyroid hormone biosynthesis. Correlation of conversion of biosynthetic precursors with intracellular protein migration as determined by electron microscope autoradiography. J Cell Biol 80:715-731.
40. Canaff L, Bennett HP, Hou Y, Seidah NG, Hendy GN (1999) Proparathyroid hormone processing by the proprotein convertase-7: comparison with furin and assessment of modulation of parathyroid convertase messenger ribonucleic acid levels by calcium and 1, 25-dihydroxyvitamin D3. Endocrinology 140:3633-3642.
41. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Milstone L, Barton DE et al. (1988) Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 85:597-601.
42. Yasuda T, Banville D, Hendy GN, Goltzman D (1988) Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: Evidence for the alternative splicing of a single-copy gene. Proc Natl Acad Sci USA 85:4605-4609.
43. Guise TA (1997) Parathyroid hormone-related protein and bone metastases. Cancer 80:1572-1580.
44. Liu B, Amizuka N, Goltzman D, Rabbani SA (1995) Inhibition of processing of parathyroid hormone-related peptide by anti-sense furin: Effect in vitro and in vivo on rat Leydig (H-500) tumor cells. Int J Cancer 63:276-281.
45. Dawas K, Loizidou M, Shankar A, Ali H, Taylor I (1999) Angiogenesis in cancer: The role of endothelin-1. Ann R Coll Surg Engl 81:306-310.
46. Bagnato A, Spinella F (2003) Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 14:44-50.
47. Blais V, Fugere M, Denault JB, Klarskov K, Day R, Leduc R (2002) Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett 524:43-48.
48. Kido T, Sawamura T, Hoshikawa H, D'Orleans-Juste P, Denault JB, Leduc R, Kimura J, Masaki T (1997) Processing of proendothelin-1 at the C-terminus of big endothelin-1 is essential for proteolysis by endothelin-converting enzyme-1 in vivo. Eur J Biochem 244:520-526.
49. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE (2005) Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146:3883-3891.
50. Fukumoto S, Yamashita T (2002) Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11:385-389.
51. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active fulllength FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960.
52. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182.
53. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomaldominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086.
54. Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T (2005) Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23:435-440.
55. Bibel M, Barde YA (2000) Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 14:2919-2937.
56. Lee FS, Kim AH, Khursigara G, Chao MV (2001) The uniqueness of being a neurotrophin receptor. Curr Opin Neurobiol 11:281-286.
57. Denkins Y, Reiland J, Roy M, Sinnappah-Kang ND, Galjour J, Murry BP, Blust J, Aucoin R, Marchetti D (2004) Brain metastases in melanoma: roles of neurotrophins. Neuro-oncol 6:154-165.
58. Bothwell M (1995) Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 18:223-253.
59. Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381-391.
60. Roux PP, Barker PA (2002) Neurotrophin signaling through the p75NTR neurotrophin receptor. Prog Neurobiol 67:203-233.
61. Mowla SJ, Farhadi HF, Pareek S, Atwal JK, Morris SJ, Seidah NG, Murphy RA (2001) Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 276:12660-6.
62. Chao MV, Bothwell M (2002) Neurotrophins: To cleave or not to cleave. Neuron 33:9-12.
63. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, Schwarz E, Willnow TE, Hempstead BL, Petersen CM (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427:843-848.
64. Fayard B, Loeffler S, Weis J, Vogelin E, Kruttgen A (2005) The secreted brain-derived neurotrophic factor precursor pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC. J Neurosci Res 80:18-28.